Galactomannan C

N/A

Report date: 2023/02/20 20:00:21
NME

Base Information

Drug NameGalactomannan C
Drug Alias NameCarbohydrate polymerDAVANATGM-CT-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGalectin-3 inhibitors
TargetsGalectin-3
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Prostatic NeoplasmsLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGalectin Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBioXyTran Inc
Inactive CompaniesCliniques Universitaires Saint-Luc A.S.B.L.Galectin Therapeutics Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsProstatic NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A